Abstract:All-trans-retinoic acid (ATRA), the biologically most active metabolite of vitamin A, plays a major role in the regulation of cellular differentiation and proliferation, and it is also an important pharmacological agent particularly used in the treatment of cancer, skin, neurodegenerative and autoimmune diseases. However, ATRA is very easy to be metabolized into 4-hydroxyl-RA in vivo by CYP26A1, an inducible cytochrome P450 enzyme, eventually into more polar metabolites. Therefore, it is vital to develop specific retinoic acid metabolism blocking agents (RAMBAs) to inhibit the metabolic enzyme CYP26A1 in the treatment of relevant diseases aforementioned.In this study, CYP26A1 and its interactions with retinoic acid-competitive metabolism blocking agents were investigated by a combined ligand- and structure-based approach. First, since the crystal structure of CYP26A1 protein has not been determined, we constructed the 3D structure of CYP26A1 using homology modeling. In order to achieve a deeper insight into the mode of action of RAMBAs in the active site, the molecular superimposition model and the common feature pharmacophore model were constructed, and molecular docking was performed. The molecular superimposition model is composed of three features: the main chain groups, side chain groups, and azole groups. The common feature pharmacophore model consists of five chemical features: four hydrophobic groups and one hydrogen acceptor (HHHHA). The results of molecular docking show that the characteristic groups of RAMBAs were mapped into three different active pockets, respectively.A structure-activity relationship (SAR) was obtained by a combination of the molecular superimposition and docking results with the pharmacophore model. This study gives more insight into the interaction model inside the CYP26A1 active site and provides guidance for the design of more potent and possibly more selective RAMBAs. (C) 2014 Elsevier Inc. All rights reserved.

The evolution paths of some reprehensive scaffolds of RORt modulators, a perspective from medicinal chemistry

Development and therapeutic potential of allosteric retinoic acid receptor-related orphan receptor ?t (ROR?t) inverse agonists for autoimmune diseases

The Pathophysiological Roles and Regulatory Mechanism of Retinoic Acid Receptor-related Orphan Receptors

Molecular Recognition of CYP26A1 Binding Pockets and Structure–activity Relationship Studies for Design of Potent and Selective Retinoic Acid Metabolism Blocking Agents

3D-QSAR, molecular docking and molecular dynamics studies of a series of RORγt inhibitors.

Modes of Action Insights from the Crystallographic Structures of Retinoic Acid Receptor-Related Orphan Receptor-Γt (Rorγt)

Discovery and Structural Optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1h)-ones As RORc Inverse Agonists

Discovery of <i>tert</i>-amine-based RORt agonists

Investigations of Retinoic Acid Receptor-Related Orphan Receptor-Gamma T (rorγt) Agonists: a Combination of 3D-QSAR, Molecular Docking and Molecular Dynamics

Discovery of novel triazine derivatives as potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists

ROR Nuclear Receptors: Structures, Related Diseases, and Drug Discovery

Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation.

Discovery of Biaryl Amide Derivatives As Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.

Discovery of Novel N-sulfonamide-tetrahydroisoquinolines As Potent Retinoic Acid Receptor-Related Orphan Receptor Γt Agonists

Crystallography-guided discovery of carbazole-based retinoic acid-related orphan receptor gamma-t (RORγt) modulators: insights into different protein behaviors with “short” and “long” inverse agonists

Discovery of 2H-Chromone-4-one Based Sulfonamide Derivatives As Potent Retinoic Acid Receptor-Related Orphan Receptor Γt Inverse Agonists.

Discovery of tert-amine-based RORγt agonists.

Antitumor studies on celastrol and its derivatives as RORα agonists and RORγ inhibitors based on Alphafold reverse docking strategy

Molecular Mechanism of Action of RORγt Agonists and Inverse Agonists: Insights from Molecular Dynamics Simulation

Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORt agonists

Lithocholic acid derivatives as potent modulators of the nuclear receptor RORγt